Company
TPST -0.93%Tempest Therapeutics, Inc.
Market Cap: $12.7 Million
USD as of Aug 2, 2026
$TPST -0.93% $TPST United States Healthcare Biotechnology US Healthcare US BiotechnologyTempest Therapeutics, Inc. Market Capitalization Over Time
View HistoryEvolution of Tempest Therapeutics, Inc. market cap in the past 5 years
Market capitalizations are calculated from the opening stock price at the beginning of each month.
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $209.25 B |
| Vertex Pharmaceuticals | $121.09 B |
| Regeneron Pharmaceuticals | $78.52 B |
| argenx | $52.93 B |
| Beigene Ltd. | $51.33 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
| Lilly | $1.024 T |
| Johnson & Johnson | $617.78 B |
| AbbVie | $443.36 B |
| Roche | $418.93 B |
| UnitedHealth Group | $376.34 B |
Detailed Description
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is headquartered in South San Francisco, California.
Financials
| Last Financial Reports Date | None |
| Revenue TTM | $None |
| EBITDA | $None |
| Gross Profit TTM | $None |
| Profit Margin | % |
| Operating Margin | % |
| Quarterly Revenue Growth | % |
Stocks & Indexes
Tempest Therapeutics, Inc. main stocks and indexes inclusions.
$TPSTNASDAQ Composite